Viewing data from:

NITROFURANTOIN

ANDA

NITROFURANTOIN, MACROCRYSTALLINE | A073652 | IMPAX LABORATORIES INC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: MACRODANTIN(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Nitrofurantoin (2023)

Total Spending

$24.6M

Total Claims

655,227

Beneficiaries

313,690

Avg Cost/Unit

$1.11

Spending Trend

$5.2M(2019)→$28.3M(2019)→$7.3M(2020)→$28.9M(2020)→$7.8M(2021)→$28.3M(2021)→$27.4M(2022)→$7.3M(2022)→$8.1M(2023)→$24.6M(2023)

YoY Change:-9.9%

5yr CAGR:-3.1%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 100MG

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Jan 28, 1993

No patent or exclusivity listings for this strength.